US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock Life Science Spring Summit with Initiator Pharma

Do not miss Initiator Pharma’s presentation at the BioStock Life Science Spring Summit, today May 31 at 12.10. The event starts at 10.00 - see the full programme on BioStock's website  or YouTube channel .CEO Claus Elsborg Olesen will present Initiator Pharma at the BioStock Life Science Spring Summit , starting at 12.10.  This is a press release from BioStock – Connecting Innovation & Capital (

Initiator Pharma A/S has been approved for listing on the Nasdaq First North Growth Market

Initiator Pharma A/S (“Initiator” or “the Company”) has today received approval for admission to trading on the Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is October 25, 2021.Nasdaq Stockholm today announced that Initiator Pharma meets the listing requirements on Nasdaq First North Growth Market and the Company has received approval for admission to trading on Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is October 25, 2021. Initiator Pharma's share is currently listed on Spotlight Stock

Correction of previously published press release regarding CTA-filing for Phase I study

The press release published by Initiator Pharma at 03:52 p.m. today, October 19, 2021, “Initiator Pharma files CTA for Phase I study with IP2105 in relation to assessment of pain reducing effects ”, included incorrect information regarding the names of Initiator Pharma’s clinical programs. A corrected version of the press release is as follows. Initiator Pharma files CTA for Phase I study for the IPTN2021 program in relation to assessment of pain reducing effects Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today that it has filed a Clinical Trials Application

Initiator Pharma files CTA for Phase I study with IP2105 in relation to assessment of pain reducing effects

Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today that it has filed a Clinical Trials Application for its planned Phase I study with IP2105 in healthy subjects challenged with pain inducing ingredient (capsaicin)Initiator Pharma has filed its Clinical Trial Application (CTA) for its planned Phase I study in healthy male subjects with IP2015 to the Medicines & Healthcare products Regulatory Agency, MHRA, UK. Subject inclusion and dosing is expected January 2022. The study will be carried out in collaboration with MAC Clinical Research, UK, as a single site study.

Initiator Pharma A/S publishes information memorandum in connection with the change of listing to Nasdaq First North Growth Markets

On Monday October 7, 2021 Nasdaq Stockholm AB approved Initiator Pharma A/S (“Initiator Pharma” or the “Company”) application for admission to trading of the Company’s shares on Nasdaq First North Growth Markets in Stockholm. Today, the Company publishes an information memorandum, in accordance with Nasdaq First North Growth Markets rules for application.The memorandum is available as attached pdf file and on the Company’s website https://initiatorpharma.com/investors/. The memorandum is not a prospectus, has not been approved by the Danish Financial Supervisory Authority (Dk.

Initiator Pharma A/S receives conditional approval for listing of its shares on to Nasdaq First North Growth Market in Stockholm

PRESS RELEASE 8 October 2021 Initiator Pharma A/S ("Initiator Pharma" or "the Company") has applied for and received conditional approval for admission to trading of its shares on Nasdaq First North Growth Market Stockholm ("Nasdaq First North") which is operated by Nasdaq Stockholm AB. As a result, the Company's application for delisting has also been approved by Spotlight Stock Market. The last day for trading for the Company´s shares on the Spotlight Stock Market is October 22, 2021. The first day of trading of the Company’s shares on Nasdaq First North is October 25, 2021.

Result of incentive program in Initiator Pharma A/S

PRESS RELEASE 1 October 2021 The AGM held on May 28, 2021 approved a long-term incentive program (“LTI2021”) for key personnel and board members. Under this program the board is authorized to allow participants in the program to acquire up to 220.000 ordinary shares in the market at market price (“Investment Shares”) until September 30, 2021, with each Investment Share carrying the right to subscribe for 1 new share at par value at the next AGM providing that the individual owning the Investment Share is still with the company at the time (“Matching Share”). Each Investment Share

Initiator Pharma includes the first patient in Phase 2b study with IPED2015 in Erectile Dysfunction patients

PRESS RELEASE                 September 24, 2021 Initiator Pharma A/S, a clinical-stage life science company, announced today that it has dosed the first patient in the Phase 2b study in Erectile Dysfunction (ED) patients with the drug candidate IPED2015. The study is carried out in collaboration with MAC Clinical Research, UK, at multiple centers across UK.“IPED2015 is our most advanced ED program with potential to become a new treatment method for the large group of patients that do not respond to the currently marketed drugs in the PDE5i class, such as Viagra and Cialis. The dosing

Initiator Pharma signs screening agreement with the US National Institute on Drug Abuse to evaluate anti-addictive properties of preclinical assets

PRESS RELEASE September 17, 2021                                                                                   Initiator Pharma A/S, a clinical-stage Life Science company, today announced that it has signed a screening agreeement with the National Institute on Drug Abuse (NIDA) in the USA in order to investigate the potential benefits of the company’s preclinical assets IPDP2015 and IPNP2015 for improved treatment of addiction.Initiator Pharma has signed a screening agreement with the National Institute on Drug Abuse (NIDA), www.nida.nih.gov, part of the National Institutes of

INITIATOR PHARMA: INTERIM REPORT JANUARY- JUNE 2021

Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016. Second Quarter (2021-04-01 – 2021-06-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -4,944 (-3,013) · Earnings per share was DKK –0.14 (-0.13) First Six Months of the Year (2021-01-01 – 2021-06-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -6,736 (-5,405) · Earnings per share was DKK –0.19 (-0.23) · Cash and bank: TDKK 31,099 (8,189) · Solidity:

Last day of trading in BTA in Initiator Pharma A/S

PRESS RELEASE                 13 August 2021 In July 2021, Initiator Pharma A/S (”Initiator Pharma”) conducted a rights issue in which the general public was given the opportunity to subscribe. Through the rights issue, a total of 7,958,628 shares were issued. The rights issue has now been registered at the Danish Business Authority and the last day of trading in BTA (paid for shares) is on the 18[th] of August 2021. The stop date will be on the 20[th] of August 2021.A total of 7,958,628 new shares have been registered at the Danish Business Authority. These are estimated to be

Initiator Pharma A/S rights issue oversubscribed

On July 26, 2021, the subscription period in Initiator Pharma A/S (“Initiator Pharma” or “the Company”) rights issue of shares ended. The rights issue was subscribed for to a total of approximately 227 percent by existing shareholders, the public and through pre-subscription commitments. Thus, none of the underwriting commitments had to be activated. The Company is provided the total issue volume of approximately SEK 29.4 million before issue costs. Settlement notes are scheduled to be sent out today, 29 July 2021.“We are thrilled to have secured funding to drive our exciting projects

Today, the subscription period begins in Initiator Pharma's rights issue

Today, 12 July 2021, the subscription period begins in Initiator Pharma A/S (“Initiator Pharma” or “the Company”) rights issue of shares in which the public is also given the opportunity to subscribe. The subscription period runs until and including 26 July 2021. A fully subscribed rights issue provides the Company with a maximum of approximately SEK 29.4 million before issue costs. Prior to the rights issue, Initiator Pharma has through written agreements agreed on subscription commitments and underwriting commitments corresponding to a total of 100 percent of the issue amount.The capital

Publication of prospectus prior to Initiator Pharma A/S preferential rights issue

Initiator Pharma A/S (“Initiator Pharma” or “the Company”) today announces that Finanstilsynet has approved the Company's prospectus for the forthcoming preferential rights issue and that the Company today publishes the prospectus on the Company’s website. The prospectus can be found through the following link https://initiatorpharma.com/investors/Preferential-Rights-Issue-2021/. The subscription period for the preferential rights issue will take place between 12 July and 26 July 2021. Teaser and subscription forms will be published in connection with the start of the subscription period.

The Board of Directors of Initiator Pharma A/S decides on execution of previously communicated preferential rights issue

The Board of Directors of Initiator Pharma A / S (“Initiator Pharma” or “the Company”) has today decided on execution of a preferential rights issue (which has previously been communicated) with the support of authorization from the Extraordinary General Meeting on May 11, 2021. The terms and preliminary schedule for the issue, which has previously been determined and communicated through a press release, are presented below. It is noted that the Board of Directors has the right to postpone the subscription period in the issue, in the event that Finanstilsynet does not approve the Company's

Initiator Pharma receives CTA approval for Phase 2b study with IPED2015 in Erectile Dysfunction patients

Initiator Pharma A/S, a clinical-stage life science company, announced today that it has received final approvals for the Clinical Trial Application (CTA) for its planned Phase 2b study in Erectile Dysfunction patients with IPED2015 from both the Medicines & Healthcare products Regulatory Agency, MHRA, UK and the Ethics Committee. The patient recruitment is expected to start at end of July. The study will be carried out in collaboration with MAC Clinical Research, UK, at multiple centers across UK.“IPED2015 is our most advanced ED candidate with potential to become a new treatment method

Estimated time plan for execution of upcoming preferential rights issue in Initiator Pharma A/S

As previously communicated, Initiator Pharma A/S (“Initiator Pharma” or “the Company”) intends to carry out a preferential rights issue of a total of approximately SEK 29.4 million (before issue costs), which has been agreed in advance in writing through subscription and guarantee commitments to 100 percent. The Company's prospectus is for review by Finanstilsynet Danmark and the Company hereby communicates an estimated time plan for the implementation of the preferential rights issue. The terms of the issue, which have previously been decided and communicated through a press release, are

Initiator Pharma - Phase 2a study with IP2018 update

Initiator Pharma A/S, a clinical-stage Life Science company today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency, MHRA, UK and the Ethics Committee for optimizing the study execution of its Phase 2a study with IP2018.As previously communicated the recruitment rate for the randomised, double-blind, placebo-controlled, 3-way crossover trial studying the efficacy and safety of IP2018 in depressed, Erectile Dysfunction (ED) Patients has been slow due to the ongoing Covid-19 pandemic. In order to mitigate the situation and ensure a

INITIATOR PHARMA: INTERIM REPORT JANUARY- MARCH 2021

Business highlights in Q1 2021 · On January 14[th] the EGM approved the proposed convertible financing agreement with MAC Clinical Research, covering up to SEK 23 million (approx. DKK 17 million) of the clinical trial costs for the planned Phase 2b trial with IPED2015 in Erectile Dysfunction. Significant events after this reporting period­ · On April 13[th] it was announced a proposal for a directed issue and fully guaranteed preferential rights issue of total SEK 60 million to expand into new orphan drug indication, led by long-term investors Linc AB and Adrigo Asset

Directed share issue registered at the Danish Companies Registration Office

The Extra General Meeting in Initiator Pharma A/S (“Initiator Pharma” or “the Company”) decided, on the 11[th] of May 2021, to approve the Board of Directors proposal to execute a directed share issue of approx. SEK 30 million. Registration of the directed share issue at the Danish Companies Registration Office has now taken place and the total number of shares amounts to 35,813,834 and the share capital to DKK 3,760,452.57.Upcoming preferential rights issue As previously communicated, the Company intends to carry out a fully secured preferential rights issue of a total of approximately

Annual report 2020 for Initiator Pharma A/S

Initiator Pharma’s annual report for 2020 is now available on the company´s home page http://initiatorpharma.com/investors/financial-reports/ For more information about Initiator Pharma, please contact: Claus Elsborg Olesen, CEOTelephone number: +45 6126 0035 E-mail: ceo@initiatorpharma.com About Initiator Pharma Initiator Pharma is a clinical-stage biotechnology company based in Aarhus, Denmark. The company’s main clinical Phase assets are IPED2015, intended for patients with erectile dysfunction, and IP2018, for the treatment of psychogenic erectile dysfunction. The

Initiator Pharma proposes directed issue and fully guaranteed preferential rights issue totaling SEK 60 million to expand into new orphan indication-led by long-term investors Linc and Adrigo

Initiator Pharma A/S (”Initiator Pharma” or ”the Company") today announces that the Board of Directors has decided to propose an Extra General Meeting (“EGM”) to resolve a proposal enabling a capitalization of a total of SEK 60 million to finance the expansion of Initiator Pharma’s clinical pipeline with its proprietary clinical program – IPTN2021 – targeting an orphan drug indication in severe neuropathic pain, Trigeminal Neuralgia. The proposal from the Board of Directors to the EGM is to resolve on a directed share issue of approximately SEK 30.0 million and a fully guaranteed preferential

INITIATOR PHARMA: YEAR END REPORT 2020

Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Fourth Quarter (2020-10-01 – 2020-12-31) · Net revenues were TDKK 0 (0) · Operating loss, EBIT was TDKK -2,069 (-2,503) · Earnings per share was DKK –0.01 (-0.06) Full Year (2020-01-01 – 2020-12-31) · Net revenues were TDKK 0 (0) · Operating loss, EBIT was TDKK -10,531 (-9,339) · Earnings per share was DKK –0.32 (-0.34) · Cash and bank: TDKK 13,504 (7,562) · Solidity: 92% (87%) Group earnings per share:

There are no items matching the current filter
There are no more items matching the current filter
Back to top